Outcome of intraoperative brachytherapy as a salvage treatment for locally recurrent rectal cancer.
Boost
High-dose radiotherapy
Intraoperative radiotherapy
Rectal cancer
Recurrence
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
received:
11
04
2024
accepted:
02
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
Locally advanced recurrent rectal cancer (RRC) requires a multimodal approach. Intraoperative high-dose-rate brachytherapy (HDR-BT) may reduce the risk of local recurrence. However, the optimal therapeutic regimen remains unclear. The aim of this retrospective monocentric study was to evaluate the toxicity of HDR-BT after resection of RRC. Between 2018 and 2022, 17 patients with RRC received resection and HDR-BT. HDR-BT was delivered alone or as an anticipated boost with a median dose of 13 Gy (range 10-13 Gy) using an A total of 17 patients were treated by HDR-BT with median dose of 13 Gy (range 10-13 Gy). Most patients (47%) had an RRC tumor stage of cT3‑4 N0. At the time of RRC diagnosis, 7 patients (41.2%) had visceral metastases (hepatic, pulmonary, or peritoneal) in the sense of oligometastatic disease. The median interval between primary tumor resection and diagnosis of RRC was 17 months (range 1-65 months). In addition to HDR-BT, 2 patients received long-course chemoradiotherapy (CRT; up to 50.4 Gy in 1.8-Gy fractions) and 2 patients received short-course CRT up to 36 Gy in 2‑Gy fractions. For concomitant CRT, all patients received 5‑fluorouracil (5-FU) or capecitabine. Median follow-up was 13 months (range 1-54). The most common acute grade 1-2 toxicities were pain in 7 patients (41.2%), wound healing disorder in 3 patients (17.6%), and lymphedema in 2 patients (11.8%). Chronic toxicities were similar: grade 1-2 pain in 7 patients (41.2%), wound healing disorder in 3 patients (17.6%), and incontinence in 2 patients (11.8%). No patient experienced a grade ≥3 event. Reirradiation using HDR-BT is well tolerated with low toxicity. An individualized multimodality approach using HDR-BT in the oligometastatic setting should be evaluated in prospective multi-institutional studies.
Sections du résumé
BACKGROUND
BACKGROUND
Locally advanced recurrent rectal cancer (RRC) requires a multimodal approach. Intraoperative high-dose-rate brachytherapy (HDR-BT) may reduce the risk of local recurrence. However, the optimal therapeutic regimen remains unclear. The aim of this retrospective monocentric study was to evaluate the toxicity of HDR-BT after resection of RRC.
METHODS
METHODS
Between 2018 and 2022, 17 patients with RRC received resection and HDR-BT. HDR-BT was delivered alone or as an anticipated boost with a median dose of 13 Gy (range 10-13 Gy) using an
RESULTS
RESULTS
A total of 17 patients were treated by HDR-BT with median dose of 13 Gy (range 10-13 Gy). Most patients (47%) had an RRC tumor stage of cT3‑4 N0. At the time of RRC diagnosis, 7 patients (41.2%) had visceral metastases (hepatic, pulmonary, or peritoneal) in the sense of oligometastatic disease. The median interval between primary tumor resection and diagnosis of RRC was 17 months (range 1-65 months). In addition to HDR-BT, 2 patients received long-course chemoradiotherapy (CRT; up to 50.4 Gy in 1.8-Gy fractions) and 2 patients received short-course CRT up to 36 Gy in 2‑Gy fractions. For concomitant CRT, all patients received 5‑fluorouracil (5-FU) or capecitabine. Median follow-up was 13 months (range 1-54). The most common acute grade 1-2 toxicities were pain in 7 patients (41.2%), wound healing disorder in 3 patients (17.6%), and lymphedema in 2 patients (11.8%). Chronic toxicities were similar: grade 1-2 pain in 7 patients (41.2%), wound healing disorder in 3 patients (17.6%), and incontinence in 2 patients (11.8%). No patient experienced a grade ≥3 event.
CONCLUSION
CONCLUSIONS
Reirradiation using HDR-BT is well tolerated with low toxicity. An individualized multimodality approach using HDR-BT in the oligometastatic setting should be evaluated in prospective multi-institutional studies.
Identifiants
pubmed: 39115680
doi: 10.1007/s00066-024-02271-1
pii: 10.1007/s00066-024-02271-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Benson AB, Venook AP, Al-Hawary MM, Azad N, Chen YJ, Ciombor KK et al (2022) Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 20(10):1139–1167
doi: 10.6004/jnccn.2022.0051
pubmed: 36240850
Conroy T, Bosset JF, Etienne PL, Rio E, Francois E, Mesgouez-Nebout N et al (2021) Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22(5):702–715
doi: 10.1016/S1470-2045(21)00079-6
pubmed: 33862000
Fokas E, Allgauer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R et al (2019) Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J Clin Oncol 37(34):3212–3222
doi: 10.1200/JCO.19.00308
pubmed: 31150315
Fokas E, Schlenska-Lange A, Polat B, Klautke G, Grabenbauer GG, Fietkau R et al (2022) Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO/AIO-12 randomized clinical trial. JAMA Oncol 8(1):e215445
doi: 10.1001/jamaoncol.2021.5445
pubmed: 34792531
Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N et al (2022) Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 40(15):1681–1692
doi: 10.1200/JCO.21.01667
pubmed: 35263150
pmcid: 9113208
Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740
doi: 10.1056/NEJMoa040694
pubmed: 15496622
Downing A, Glaser AW, Finan PJ, Wright P, Thomas JD, Gilbert A et al (2019) Functional outcomes and health-related quality of life after curative treatment for rectal cancer: a population-level study in england. Int J Radiat Oncol Biol Phys 103(5):1132–1142
doi: 10.1016/j.ijrobp.2018.12.005
pubmed: 30553942
Wolff HA, Conradi LC, Beissbarth T, Leha A, Hohenberger W, Merkel S et al (2013) Gender affects acute organ toxicity during radiochemotherapy for rectal cancer: long-term results of the German CAO/ARO/AIO-94 phase III trial. Radiother Oncol 108(1):48–54
doi: 10.1016/j.radonc.2013.05.009
pubmed: 23768685
Verheij FS, Omer DM, Williams H, Lin ST, Qin LX, Buckley JT et al (2024) Long-term results of organ preservation in patients with rectal Adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 42(5):500–506
doi: 10.1200/JCO.23.01208
pubmed: 37883738
Garcia-Aguilar J, Patil S, Gollub MJ, Kim JK, Yuval JB, Thompson HM et al (2022) Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol 40(23):2546–2556
doi: 10.1200/JCO.22.00032
pubmed: 35483010
pmcid: 9362876
Schrag D, Shi Q, Weiser MR, Gollub MJ, Saltz LB, Musher BL et al (2023) Preoperative treatment of locally advanced rectal cancer. N Engl J Med 389(4):322–334
doi: 10.1056/NEJMoa2303269
pubmed: 37272534
pmcid: 10775881
Mantello G, Galofaro E, Caravatta L, Di Carlo C, Montrone S, Arpa D et al (2023) Pattern of care for re-irradiation in locally recurrent rectal cancer: a national survey on behalf of the AIRO gastrointestinal tumors study group. Radiol Med 128(7):869–876
doi: 10.1007/s11547-023-01652-3
pubmed: 37365381
pmcid: 10317862
Swartjes H, van Rees JM, van Erning FN, Verheij M, Verhoef C, de Wilt JHW et al (2023) Locally recurrent rectal cancer: toward a second chance at cure? A population-based, retrospective cohort study. Ann Surg Oncol 30(7):3915–3924
doi: 10.1245/s10434-023-13141-y
pubmed: 36790731
pmcid: 10250482
Hagemans JAW, van Rees JM, Alberda WJ, Rothbarth J, Nuyttens J, van Meerten E et al (2020) Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. Eur J Surg Oncol 46(3):448–454
doi: 10.1016/j.ejso.2019.10.037
pubmed: 31761506
Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C et al (2006) Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: a multicentric phase II study. Int J Radiat Oncol Biol Phys 64(4):1129–1139
doi: 10.1016/j.ijrobp.2005.09.017
pubmed: 16414206
Voogt ELK, Nordkamp S, Nieuwenhuijzen GAP, Creemers GJ, Peulen HMU, Rutten HJT et al (2021) Curative treatment of locally recurrent rectal cancer: is induction chemotherapy warranted? Br J Surg 108(6):e213–e4
doi: 10.1093/bjs/znab065
pubmed: 33709100
Denost Q, Frison E, Salut C, Sitta R, Rullier A, Harji D et al (2021) A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer—GRECCAR 15 trial protocol. Colorectal Dis 23(7):1909–1918
doi: 10.1111/codi.15670
pubmed: 33843133
Cisel B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E et al (2019) Long-course preoperative chemoradiation versus 5 x 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized polish II study. Ann Oncol 30(8):1298–1303
doi: 10.1093/annonc/mdz186
pubmed: 31192355
Rodel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16(8):979–989
doi: 10.1016/S1470-2045(15)00159-X
pubmed: 26189067
Glimelius B (2003) Recurrent rectal cancer. The pre-irradiated primary tumour: can more radiotherapy be given? Colorectal Dis 5(5):501–503
doi: 10.1046/j.1463-1318.2003.00501.x
pubmed: 12925089
Bosman SJ, Holman FA, Nieuwenhuijzen GA, Martijn H, Creemers GJ, Rutten HJ (2014) Feasibility of reirradiation in the treatment of locally recurrent rectal cancer. Br J Surg 101(10):1280–1289
doi: 10.1002/bjs.9569
pubmed: 25049111
Calvo FA, Sole CV, Rutten HJ, Dries WJ, Lozano MA, Cambeiro M et al (2020) ESTRO/ACROP IORT recommendations for intraoperative radiation therapy in locally recurrent rectal cancer. Clin Transl Radiat Oncol 24:41–48
pubmed: 32613091
pmcid: 7320231
Voogt ELK, van Rees JM, Hagemans JAW, Rothbarth J, Nieuwenhuijzen GAP, Cnossen JS et al (2021) Intraoperative electron beam radiation therapy (IOERT) versus high-dose-rate Intraoperative brachytherapy (HDR-IORT) in patients with an R1 resection for locally advanced or locally recurrent rectal cancer. Int J Radiat Oncol Biol Phys 110(4):1032–1043
doi: 10.1016/j.ijrobp.2021.02.006
pubmed: 33567303
Harrison LB, Minsky BD, Enker WE, Mychalczak B, Guillem J, Paty PB et al (1998) High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer. Int J Radiat Oncol Biol Phys 42(2):325–330
doi: 10.1016/S0360-3016(98)00211-9
pubmed: 9788411
Keogh C, O’Sullivan NJ, Temperley HC, Flood MP, Ting P, Walsh C et al (2023) Redo pelvic surgery and combined metastectomy for locally recurrent rectal cancer with known oligometastatic disease: a multicentre review. Cancers 15(18)
Rodel C, Grabenbauer GG, Matzel KE, Schick C, Fietkau R, Papadopoulos T et al (2000) Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum 43(3):312–319
doi: 10.1007/BF02258294
pubmed: 10733111
Terezakis S, Morikawa L, Wu A, Zhang Z, Shi W, Weiser MR et al (2015) Long-term survival after high-dose-rate Brachytherapy for locally advanced or recurrent colorectal adenocarcinoma. Ann Surg Oncol 22(7):2168–2178
doi: 10.1245/s10434-014-4271-8
pubmed: 25631062
pmcid: 5316234
Calvo FA, Sole CV, Alvarez de Sierra P, Gomez-Espi M, Blanco J, Lozano MA et al (2013) Prognostic impact of external beam radiation therapy in patients treated with and without extended surgery and intraoperative electrons for locally recurrent rectal cancer: 16-year experience in a single institution. Int J Radiat Oncol Biol Phys 86(5):892–900
doi: 10.1016/j.ijrobp.2013.04.008
pubmed: 23845842
Roeder F, Goetz JM, Habl G, Bischof M, Krempien R, Buechler MW et al (2012) Intraoperative electron radiation therapy (IOERT) in the management of locally recurrent rectal cancer. BMC Cancer 12:592
doi: 10.1186/1471-2407-12-592
pubmed: 23231663
pmcid: 3557137
Alektiar KM, Zelefsky MJ, Paty PB, Guillem J, Saltz LB, Cohen AM et al (2000) High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer. Int J Radiat Oncol Biol Phys 48(1):219–226
doi: 10.1016/S0360-3016(00)00634-9
pubmed: 10924992
Haddock MG, Gunderson LL, Nelson H, Cha SS, Devine RM, Dozois RR et al (2001) Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients. Int J Radiat Oncol Biol Phys 49(5):1267–1274
doi: 10.1016/S0360-3016(00)01528-5
pubmed: 11286833
Sorrentino L, Belli F, Valvo F, Villa S, Guaglio M, Scaramuzza D et al (2020) Neoadjuvant (re)chemoradiation for locally recurrent rectal cancer: Impact of anatomical site of pelvic recurrence on long-term results. Surg Oncol 35:89–96
doi: 10.1016/j.suronc.2020.08.017
pubmed: 32858390
Mohiuddin M, Marks G, Marks J (2002) Long-term results of reirradiation for patients with recurrent rectal carcinoma. Cancer 95(5):1144–1150
doi: 10.1002/cncr.10799
pubmed: 12209702
Chung SY, Koom WS, Keum KC, Chang JS, Shin SJ, Ahn JB et al (2019) Treatment outcomes of re-irradiation in Locoregionally recurrent rectal cancer and clinical significance of proper patient selection. Front Oncol 9:529
doi: 10.3389/fonc.2019.00529
pubmed: 31275858
pmcid: 6593136
Westberg K, Palmer G, Hjern F, Holm T, Martling A (2019) Population-based study of surgical treatment with and without tumour resection in patients with locally recurrent rectal cancer. Br J Surg 106(6):790–798
doi: 10.1002/bjs.11098
pubmed: 30776087
Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A et al (2022) Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial. Lancet Oncol 23(9):1189–1200
doi: 10.1016/S1470-2045(22)00446-6
pubmed: 35952709
Rahma OE, Yothers G, Hong TS, Russell MM, You YN, Parker W et al (2021) Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial. JAMA Oncol 7(8):1225–1230
doi: 10.1001/jamaoncol.2021.1683
pubmed: 34196693
Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M et al (2022) PD‑1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med 386(25):2363–2376
doi: 10.1056/NEJMoa2201445
pubmed: 35660797
pmcid: 9492301